Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient over 18 years of age. - Patient able to read and understand the information/consent leaflet. - Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40 - Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM. - Membership of a social security scheme - Patient's signed willing to sign a consent form - For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months. - For non-GLP-1 analogue group: never taken GLP-1 analogues. Who Should NOT Join This Trial: - Pregnant or breast-feeding women. - Vulnerable patients (under guardianship) - Patients deprived of liberty Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patient over 18 years of age. * Patient able to read and understand the information/consent leaflet. * Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40 * Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM. * Membership of a social security scheme * Patient's signed informed consent * For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months. * For non-GLP-1 analogue group: never taken GLP-1 analogues. Exclusion Criteria: * Pregnant or breast-feeding women. * Vulnerable patients (under guardianship) * Patients deprived of liberty

Treatments Being Tested

OTHER

Blood GLP1

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

OTHER

Blood No treated GLP1

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Locations (1)

CHU de Nice - Hôpital de l'Archet
Nice, Alpes-maritimes, France